

Table A.1 Medicines requiring cautionary advisory labels (continued)

| Medicine | Ancillary label (number) and/or additional instruction (letter) |
|---------------------------------------|---|
| Insulins | 6 (except vial or cartridge in use), 7b, 10a |
| Interferon alfa | 6, 12 |
| Irbesartan | 11, 12†, 16† |
| Isoniazid | 3b |
| Isosorbide dinitrate | 16 |
| Isosorbide mononitrate | 16, A* |
| Isotretinoin | 8, B, D |
| Itraconazole | 5, B, D |
| Itraconazole solution | 5, C (one hour), D |
| Ivabradine | 5, 13, 18, B |
| Ketoconazole | 4 (delete iron and calcium), 5, B, D, E (dermal) |
| Ketoprofen | 10a, 12†, A*, B |
| Ketorolac | 10a, 12†, A*, B |
| Labetalol | 9, 12†, 16 |
| Lamivudine | 12 |
| Lamotrigine | 1, 9 |
| Lansoprazole | A* |
| Lanreotide | 6 |
| Lanthanum | 5, B |
| Lapatinib | 3b, 5, 12, 18 |
| Latanoprost | 7b |
| Leflunomide | A |
| Lenalidomide | 12, A |
| Lercanidipine | 9, 12†, 18, C |
| Letrozole | 12 |
| Levamisole | 2, 12 |
| Levetiracetam | 1, 9 |
| Levocabastine | 1 |
| Levodopa with decarboxylase inhibitor | 9, 16 |
| Linezolid | D, I |
| Lisinopril | 11, 12†, 16† |
| Lithium carbonate | 5, 13, B |
| Lomustine | 2, 3b, 21 |
| Lopinavir with ritonavir | 5, 6, B |
| Lorazepam | 1 or 1a, 9 |
| Losartan | 11, 12†, 16† |
| Maraviroc | 5, 16 |
| Medroxyprogesterone | 12† |
| Mefenamic acid | 10a, 12†, B |
| Mefloquine | 12 |
| Megestrol | 12 |
| Meloxicam | 10a, 12†, A*, B |
| Melphalan | 3b, 6, 21 |
| Memantine | 12† |
| Mepyramine | 1, 13 |
| Mercaptopurine | 3b, 8, 21 |
| Mesalazine (oral) | 3b*, 13, A* |
| Metformin | 10a, A*, B |

† Most appropriate during initial treatment or when dosage is increased.

* Some products have specific indications or specialised formulations or coatings which give rise to instructions different from those applicable generally to the conventional dose form. In cases of doubt concerning specific products with specialised formulations or coatings, reference should be made to the recommendations contained in the manufacturer's information.

Antacids will decrease the absorption of many medicines. Unless specifically indicated to the contrary, the administration of antacids should be separated by a period of about 2 hours from other orally administered medicines whenever possible. Similar separation of the dosing of cholestyramine, colestipol, lanthanum and sevelamer from other medicines is also recommended.